PKG

A-3 Hydrochloride is an inhibitor of PKA (cAMP-dependent protein kinase, Ki=4.3μM) and cGMP-dependent protein kinase, Ki=3.8μM, PKC (protein kinase C, Ki=47μM), casein kinase I and II, and MLCK (myosin light chain kinase) ( Ki=7.4μM).

KT 5823 is a potent, selective inhibitor of cGMP-dependent protein kinase (PKG) (in vitro IC50 = 234 nM).

Rp-8-Br-PET-cGMPS is metabolically stable, competitive inhibitor of cGKI (Ki = 30 nM) and cGKII (cGMP-dependent protein kinase G) and blocks cGMP-gated retinal type ion channels (IC50 = 25 μM).

cGMP Dependent Kinase Inhibitor Peptid is a specific cGKI (cyclic GMP-dependent protein kinase) inhibitor. Data indicates that it does not block cyclic GMP-dependent protein kinase phosphorylation of intact histones and has been used to study Plasmodium falciparum.

MBP146-78 is a potent and selective inhibitor of cGMP dependent protein kinases.

Protein kinase G inhibitor-1 is a selective inhibitor targeting protein kinase G (PKG) with an IC50 of 0.9 μM. This compound is utilized primarily in research related to mycobacterial infections, providing insights into the mechanisms of pathogenesis and potential therapeutic approaches. Its efficacy in inhibiting PKG activity makes it a valuable tool for exploring mycobacterial biology and developing novel treatments.

PI4Kβ/PKG-IN-2 is a potent dual inhibitor targeting Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). This compound demonstrates significant inhibitory activity against Plasmodium, making it a valuable tool for investigating malaria pathogenesis and potential therapeutic strategies. Its oral bioavailability further supports its use in preclinical studies aimed at understanding malaria biology.

Protein kinase G inhibitor-2 is a selective inhibitor of mycobacterial protein kinase G, exhibiting an IC50 value of 3 μM. This compound is utilized in the investigation of mycobacterial infections and their associated signaling pathways. Its efficacy as a PKG inhibitor supports research into therapeutic strategies targeting mycobacterial diseases.

Rp-8-pCPT-cGMPS sodium is a selective inhibitor of cGMP-dependent protein kinase (cGK), functioning primarily through the modulation of cGMP signaling pathways. This compound also acts as an agonist for cyclic nucleotide-gated (CNG) channels in a voltage-dependent manner, making it valuable for studying the intricate roles of cyclic nucleotides in cellular processes. Its applications extend to research in cardiovascular physiology, neurobiology, and signal transduction mechanisms.

DT-3 is a selective inhibitor of protein kinase G Iα (PKG Iα), designed to impede the cGMP-PKG signaling pathway. This membrane-permeable peptide demonstrates significant pharmacological activity, making it valuable for research applications focused on cardiovascular function and signaling related diseases. DT-3 enables the investigation of the roles of PKG Iα in various cellular processes and helps elucidate its contributions to cardiovascular health and disease.

Rp-8-pCPT-cGMPS is a competitive inhibitor of cGMP-dependent protein kinase (PKG) with a Ki value of 0.5 μM. Its high lipid solubility facilitates cellular penetration, enabling effective inhibition of PKG activity within cells. This reagent is valuable for investigating the role and function of PKG in cellular processes, particularly in platelets.